EXCLUSIVE: Medtronic’s strategy guru on the $43B Covidien buy

June 27, 2014 by Brad Perriello

Geoff Martha, the executive in charge of integrating Medtronic’s $43 billion Covidien acquisition, tells that the deal will likely mean more strategic investments for the medical device giant.

The pending $43 billion merger of Medtronic (NYSE:MDT) andCovidien (NYSE:COV) triggered speculation that the combined medical device giant would scale back on its strategic investment program. After all, there’s a lot to digest in integrating a buyout of that size, the thinking goes, and the move likely takes 2 prolific acquirers off the board.

But the opposite is true, according to Geoff Martha, the Medtronic strategy & business development executive charged with managing the integration of Covidien.



Josh Sandberg

Josh Sandberg is the President of Ortho Sales Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *